Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer

  • Technology appraisal guidance
  • TA214
  • Published: 
Download guidance (PDF)

1 Recommendations

During the appraisal, the European Medicines Agency (EMA) conducted a review of the use of bevacizumab in combination with taxanes for the treatment of metastatic breast cancer. Following that review, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended that bevacizumab, when used to treat metastatic breast cancer, should be used only in combination with the taxane paclitaxel.

1.1

Bevacizumab in combination with a taxane is not recommended for the first-line treatment of metastatic breast cancer.

1.2

Patients currently receiving bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer should have the option to continue therapy until they and their clinicians consider it appropriate to stop.